Seven years passed since docetaxel/prednisone demonstrated and overall survival benefit,
leading to its approval by the FDA for metastatic castration resistant prostate cancer. In 2010 …

Androgen deprivation therapy is the initial treatment for men with advanced prostate cancer.
Almost all these patients eventually develop progressive castration‐resistant prostate cancer …

Most men with metastatic prostate cancer respond to various types of androgen ablation but
progress to castration-resistant disease. The TAX 327 and Southwest Oncology Group …

First-line therapy for men with metastatic or recurrent prostate cancer following definitive
local therapy is medical or surgical castration. Though effective initially in most patients, the …

Docetaxel had been the only treatment of castration-resistant prostate cancer (CRPC) that
demonstrated a survival benefit for the patients. After its approval, no considerable progress …

Historically, patients diagnosed with castration-resistant prostate cancer (CRPC) have had
poor survival rates. In recent years there have been significant advances in the treatment of …

Prostate cancer is the most common non-cutaneous neoplasm in the male population
worldwide. It is typically diagnosed in its early stages, and the disease exhibits a relatively …

Most men with recurrent prostate cancer (CaP) initially respond to androgen deprivation
therapy but eventually develop metastatic castration-resistant prostate cancer (CRPC). Over …

The medical management of men with castration-resistant prostate cancer (CRPC) has
changed dramatically in the last decade. Multiple successful phase III trials have been …

OBJECTIVE: To review the activity of 3 new agents approved for the management of
advanced castration-resistant prostate cancer (CRPC): sipuleucel-T, cabazitaxel, and …